Abstract
Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Current Pharmaceutical Biotechnology
Title:Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Volume: 15 Issue: 11
Author(s): Dai Mizuno, Hironari Koyama, Susumu Ohkawara, Yutaka Sadakane and Masahiro Kawahara
Affiliation:
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Abstract: Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Export Options
About this article
Cite this article as:
Mizuno Dai, Koyama Hironari, Ohkawara Susumu, Sadakane Yutaka and Kawahara Masahiro, Involvement of Trace Elements in the Pathogenesis of Prion Diseases, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141103020625
DOI https://dx.doi.org/10.2174/1389201015666141103020625 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology Hippocampal BDNF Expression in a Tau Transgenic Mouse Model
Current Alzheimer Research Post-Transcriptional Regulation of HSP70 Expression Following Oxidative Stress in SH-SY5Y Cells: The Potential Involvement of the RNA-Binding Protein HuR
Current Pharmaceutical Design Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Current Pharmaceutical Design The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Recent Knowledge on Medicinal Plants as Source of Cholinesterase Inhibitors for the Treatment of Dementia
Mini-Reviews in Medicinal Chemistry Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design